Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:du Rusquec P" with an ORCID

Pauline du Rusquec
Institut Curie
3
Publications
273
Citations
View profile

Search results

1-25 of 26 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, [...] Cortot AB
Lung Cancer, 196:107934, 24 Aug 2024
Cited by: 0 articles | PMID: 39277916
Add to export list
Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French Cohort.
Basse C, Carton M, Milder M, Geiss R, Du Rusquec P, Daniel C, Massiani MA, Livartowski A, Girard N
Cancers (Basel), 16(15):2768, 05 Aug 2024
Cited by: 2 articles | PMID: 39123495 | PMCID: PMC11312246
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.
Huet C, Basse C, Knetki-Wroblewska M, Chilczuk P, Bonte PE, Cyrille S, Gobbini E, Du Rusquec P, Olszyna-Serementa M, Daniel C, Lucibello F, Lahmi L, Krzakowski M, Girard N
Clin Lung Cancer, S1525-7304(24)00147-5, 08 Aug 2024
Cited by: 0 articles | PMID: 39214846
Add to export list
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P
ESMO Open, 9(6):103473, 03 Jun 2024
Cited by: 0 articles | PMID: 38833966 | PMCID: PMC11179088
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Palliative care integration and end-of-life care intensity for patients with NSCLC.
Martin A, Carton M, Thery L, Burnod A, Daniel C, Du Rusquec P, Girard N, Bouleuc C
Lung Cancer, 192:107800, 24 Apr 2024
Cited by: 0 articles | PMID: 38728972
Add to export list
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, [...] DeLLphi-301 Investigators
N Engl J Med, 389(22):2063-2075, 20 Oct 2023
Cited by: 52 articles | PMID: 37861218
Add to export list
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.
du Rusquec P, Guimbaud R, Le Malicot K, Gornet JM, Nguyen S, Lecomte T, Khemissa-Akouz F, Perrier H, Bouché O, Paoletti X, Le Tourneau C
ESMO Open, 8(4):101616, 04 Aug 2023
Cited by: 0 articles | PMID: 37542912 | PMCID: PMC10485393
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancer.
Basse C, Ancel J, Massiani MA, Bonté PE, Beaulaton C, Beaucaire-Danel S, Milder M, Cao K, Daniel C, Du Rusquec P, Sablin MP, Kirova Y, Sage E, Beddok A, Girard N
Lung Cancer, 182:107295, 11 Jul 2023
Cited by: 2 articles | PMID: 37442059
Add to export list
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
Hescot S, Debien V, Hadoux J, Drui D, Haissaguerre M, de la Fouchardiere C, Vezzosi D, Do Cao C, Libé R, Le Tourneau C, Baudin E, Massard C, du Rusquec P, from the French ENDOCAN-COMETE network
Eur J Cancer, 189:112917, 16 May 2023
Cited by: 0 articles | PMID: 37277263
Add to export list
Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance.
Hescot S, Masliah-Planchon J, du Rusquec P, Dupain C, Kamal M, Servois V, Bieche I
Eur Thyroid J, 11(5):e220044, 27 Sep 2022
Cited by: 0 articles | PMID: 36053791 | PMCID: PMC9578058
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients.
Samaille T, Moreau Bachelard C, Coquan E, du Rusquec P, Paoletti X, Le Tourneau C
ESMO Open, 7(1):100366, 31 Dec 2021
Cited by: 4 articles | PMID: 34979424 | PMCID: PMC8733185
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G, Bièche I, Dupain C, Borcoman E, du Rusquec P, Ricci F, Hescot S, Sablin MP, Tresca P, Bello D, Dubot C, Loirat D, Frelaut M, Lecerf C, Le Tourneau C, Kamal M
JCO Precis Oncol, 5:215-226, 01 Nov 2021
Cited by: 11 articles | PMID: 34994597
Add to export list Review
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis.
Moreau Bachelard C, Coquan E, du Rusquec P, Paoletti X, Le Tourneau C
EClinicalMedicine, 40:101130, 04 Sep 2021
Cited by: 10 articles | PMID: 34746718 | PMCID: PMC8548931
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Drug Development in Tissue-Agnostic Indications.
du Rusquec P, Le Tourneau C
Cancers (Basel), 13(11):2758, 02 Jun 2021
Cited by: 5 articles | PMID: 34199382 | PMCID: PMC8199632
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.
Petak I, Kamal M, Dirner A, Bieche I, Doczi R, Mariani O, Filotas P, Salomon A, Vodicska B, Servois V, Varkondi E, Gentien D, Tihanyi D, Tresca P, Lakatos D, Servant N, Deri J, du Rusquec P, Hegedus C, [...] Le Tourneau C
NPJ Precis Oncol, 5(1):59, 23 Jun 2021
Cited by: 10 articles | PMID: 34162980 | PMCID: PMC8222375
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Drug development in the era of precision medicine in oncology-Clues beyond randomization.
du Rusquec P, Filleron T, Le Tourneau C
Chin Clin Oncol, 10(3):23, 23 Apr 2021
Cited by: 1 article | PMID: 33977726
Add to export list
Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.
du Rusquec P, Blonz C, Frenel JS, Campone M
Ther Adv Med Oncol, 12:1758835920940939, 28 Jul 2020
Cited by: 42 articles | PMID: 32782489 | PMCID: PMC7388095
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E
BioDrugs, 34(4):463-476, 01 Aug 2020
Cited by: 37 articles | PMID: 32394415
Add to export list Review
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M, Du Rusquec P, Romano E
Oncoimmunology, 9(1):1777064, 10 Jun 2020
Cited by: 18 articles | PMID: 32934880 | PMCID: PMC7466853
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.
Dupain C, Masliah-Planchon J, Gu C, Girard E, Gestraud P, Du Rusquec P, Borcoman E, Bello D, Ricci F, Hescot S, Sablin MP, Tresca P, de Moura A, Loirat D, Frelaut M, Vincent-Salomon A, Lecerf C, Callens C, Antonio S, [...] Servois V
Mol Oncol, 15(1):104-115, 15 Sep 2020
Cited by: 7 articles | PMID: 32750212 | PMCID: PMC7782085
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.
Manson G, Maria ATJ, Poizeau F, Danlos FX, Kostine M, Brosseau S, Aspeslagh S, Du Rusquec P, Roger M, Pallix-Guyot M, Ruivard M, Dousset L, Grignou L, Psimaras D, Pluvy J, Quéré G, Grados F, Duval F, Bourdain F, [...] Michot JM
J Immunother Cancer, 7(1):337, 03 Dec 2019
Cited by: 30 articles | PMID: 31796119 | PMCID: PMC6892018
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS
Cancer Manag Res, 11:4297-4312, 15 May 2019
Cited by: 26 articles | PMID: 31190995 | PMCID: PMC6527794
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Fatal Anti-Ma2 Encephalitis Related to Treatment of Malignant Pleural Mesothelioma With a Combination of Anti-Programmed Death 1 and Anti-Cytotoxic T-Lymphocyte Associated Protein 4 Antibodies.
Du Rusquec P, Peyre A, Toulgoat F, Honnorat J, Raimbourg J
J Thorac Oncol, 14(8):e174-e176, 01 Aug 2019
Cited by: 1 article | PMID: 31345342
Add to export list
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Caroline F, Campone M, Frenel JS
Breast Cancer Res Treat, 168(2):559-566, 15 Dec 2017
Cited by: 17 articles | PMID: 29247442
Add to export list
Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer.
Voog E, Campion L, du Rusquec P, Bourgeois H, Domont J, Denis F, Emmanuel E, Dupuis O, Ganem G, Lafont C, Le Du K, Pavluc E, Pointreau Y, Roche S, Juhel-Voog L, Zinger M, Solal-Celigny P
Support Care Cancer, 26(1):81-89, 29 Jul 2017
Cited by: 26 articles | PMID: 28756472
Add to export list

1-25 of 26 results

1 2

Search life-sciences literature (45,103,589 articles, preprints and more)

Suggested authors matching "AUTH:du Rusquec P" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:du Rusquec P" with an ORCID